Selank/Semax Blend Dosage, Reconstitution & Mixing Trends

Explore selank/semax blend calculator-entry dose, vial-size, BAC-water and self-reported frequency distributions. Research context is separate from live observations.

Anonymized selank/semax blend calculator entries are summarized by each chart's selected period. Frequency responses come from the separate vial-duration feature. Inputs are not verified administrations or unique people.

What Selank/Semax Blend Is

The Selank/Semax Blend is a research-grade combination of two Russian heptapeptides — Selank (an anxiolytic tuftsin analog) and Semax (a nootropic ACTH(4-10) analog) — packaged in one vial and most often sourced for "calm-and-focused" cognitive research. It ships as a lyophilized powder you reconstitute with bacteriostatic water. See the standalone [Selank](/vendors/selank) and [Semax](/vendors/semax) entries for full pharmacology.[1][2]

No pharmacology is unique to the blend; the proposed mechanism is the sum of the two parent peptides — Selank's GABA-A subunit-expression modulation and enkephalinase inhibition, plus Semax's BDNF/TrkB upregulation and dopaminergic-serotonergic modulation.[1][2] No study has directly characterised pharmacokinetic or pharmacodynamic interactions between the two when co-administered.

No registered clinical trial has tested the blend specifically; all published Russian clinical evidence used the two molecules as separate products.[3][4] Vendor packaging is a convenience and cost-saving format rather than a characterised combination product.

Not FDA-approved. The two constituent peptides are each registered for clinical use in the Russian Federation as separate products; the blend itself is not a registered product. Research peptide only.

Selank/Semax Blend Research Sources

Selank/Semax Blend Dosing Context

Selank/Semax Blend has a reported half-life of ~30 min (both components). The pharmacokinetic reference models an interval of twice daily (intranasal); this is not a measured community cadence or a dosing recommendation. Both peptides are very short-lived in plasma and act as pulses; neither accumulates between doses. Consistent timing matters more than total daily amount. Pharmacokinetic source: Component data: Andreeva et al. 2006 (Selank); Potaman et al. 1991 (Semax). Selank/Semax Blend is a blend of Selank and Semax, so a reconstitution figure for it covers the combined vial contents rather than any single component. It is catalogued under Memory Peptides on WPA.

Selank/Semax Blend Community Calculator Data

444 Selank/Semax Blend reconstitution calculations have been logged by the WPA community.

This is the lifetime header population. Each chart and its associated analysis below use their own selected period and denominator; frequency responses are a separate cohort.

These figures come from anonymized WPA peptide calculator sessions, not verified administrations or unique people. Separate modal inputs do not establish a joint protocol. They are community input statistics — not dosing recommendations, and not medical advice.

WPA Analysis

Selank/Semax Blend Research Background and Calculator Data

The Selank/Semax blend is a co-formulated preparation of the two heptapeptides developed at the Institute of Molecular Genetics of the Russian Academy of Sciences by the Ashmarin/Myasoedov-era research network — Selank (the tuftsin analog with a Pro-Gly-Pro stability tail) and Semax (the ACTH 4-7 fragment with the same Pro-Gly-Pro tail). The mechanistic rationale for combining the two molecules in a single preparation is straightforward overlap: Selank is positioned in the Russian clinical literature as a non-benzodiazepine anxiolytic with light cognitive effects, and Semax is positioned as a neuroprotective and cognitive-enhancing agent with a milder anxiolytic component. The two molecules have non-identical receptor profiles — Selank acts predominantly through GABAergic and serotonergic modulation, Semax through BDNF/NGF upregulation and melanocortin pathway interactions — and the implied protocol logic is that a single co-administered dose covers both phenomenological territories at once.

The published clinical record for the blend specifically (as opposed to the two molecules administered separately) is essentially absent. Both Selank and Semax have been studied independently in the Russian clinical setting at intranasal doses of 300-900mcg/day (Selank) and 200-2000mcg/day (Semax), but no Russian regulatory program has formally validated a blended preparation. No regulatory approval exists for the blend in any market, and the Western literature on the combination is essentially translation of the individual-molecule research plus user-community accumulated dose conventions.

Research background is separate from the calculator observations below. Calculator entries do not establish administration, safety, effectiveness, or the reasons for an input.

WPA DOSING INSIGHT

Dose and Frequency Calculator Inputs

The summaries use each chart's own period and, for frequency responses, its dose filter. Separate cohorts must not be combined into a protocol.

WPA RECONSTITUTION INSIGHT

Vial Size and BAC Water Calculator Inputs

Vial-size and BAC-water observations describe separate input distributions, not purchases or verified preparations. Separate modal inputs do not establish a joint protocol.

These figures come from anonymized WPA peptide calculator sessions.

All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.